From inhaler to lung: Clinical implications of the formulations of ciclesonide and other inhaled corticosteroids

International Journal of General Medicine

Volumn 6, Issue , 2013, Pages 99-107

  Nave, Ruediger ^a   Muller, Helgert ^a  

^a Nycomed GmbH   (Germany)

Author keywords

Asthma; Ciclesonide; Lung deposition; Small airways

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; PLACEBO; TECHNETIUM 99M;

AEROSOL; ASTHMA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG LABELING; DRUG SAFETY; EQUIPMENT DESIGN; HUMAN; INHALER; MAXIMUM PLASMA CONCENTRATION; METERED DOSE INHALER; OROPHARYNX; PARTICLE SIZE; PLUME; POWDER INHALER; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84875326461     PISSN: None     EISSN: 11787074     Source Type: Journal    
DOI: 10.2147/IJGM.S39134     Document Type: Review

References (50)

1. GINA [webpage on the Internet]. From the Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA); 2012. Available from: http://www.ginasthma.org/guidelines-gina-report-global-strategy-for-asthma.html. Accessed January 18, 2013.
2. Nave R. Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide. Clin Pharmacokinet. 2009;48(4):243-252.
3. Allen DB, Bielory L, Derendorf H, Dluhy R, Colice GL, Szefler SJ. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003;112(Suppl 3):S1-S40.
4. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med. 2006;100(8):1307-1317.
5. Berger W. Aerosol devices and asthma therapy. Curr Drug Deliv. 2009;6(1):38-49.
6. Everard ML, Devadason SG, Le Souëf PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med. 1997;91(10):624-628.
7. Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol. 2004;44(1):37-47.
8. Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol. 2009;124(Suppl 6):S88-S93.
9. de Vries TW, Rottier BL, Gjaltema D, Hagedoorn P, Frijlink HW, de Boer AH. Comparative in vitro evaluation of four corticosteroid metered dose inhalers: consistency of delivered dose and particle size distribution. Respir Med. 2009;103(8):1167-1173.
10. Bethke TD, Drollman A, Hauns B, et al. Bioequivalence of two cicle-sonide dosing regimen (4 puffs of 200μg versus 16 puffs of 50μg using a MDI). Eur Respir J.2002;20(Suppl 38):109s.
11. Weibel ER. Principles and methods for the morphometric study of the lung and other organs. Lab Invest. 1963;12:131-155.
12. Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(Suppl 2):S447-S460.
13. Contoli M, Bousquet J, Fabbri LM, et al. The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. Allergy. 2010;65(2):141-151.
14. Virchow JC. Asthma - a small airway disease: concepts and evidence. Pneumologie. 2009;63(Suppl 2):S96-S101.
15. Tulic MK, Hamid Q. Contribution of the distal lung to the pathologic and physiologic changes in asthma: potential therapeutic target Roger S. Mitchell lecture. Chest. 2003;123(Suppl 3):348S-355S.
16. Mitchell JP, Nagel MW, Wiersema KJ, Doyle CC. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer. AAPS Pharm Sci Tech. 2003;4(4):E54.
17. Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med. 2000;94(Suppl B):S3-S9.
18. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med. 2006;100(3):375-384.
19. Yang TT, Li S, Wyka B, Kenyon D. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med. 2001;14(4):487-494.
20. Leach CL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J. 1998;12(6):1346-1353.
21. Leach CL, Bethke T., Boudreau RJ, et al. Two-dimensional and threedimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med. 2006;19(2):117-126.
22. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497-1504.
23. Hirst PH, Bacon RE, Pitcairn GR, Silvasti M, Newman SP. A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med. 2001;95(9): 720-727.
24. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122(2):510-516.
25. Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy. 2006;61(5):518-526.
26. Mutch E, Nave R, McCracken N, Zech K, Williams FM. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol. 2007;73(10):1657-1664.
27. Nave R, McCracken N. Metabolism of ciclesonide in the upper and lower airways: review of available data. J Asthma Allergy. 2008;1:11-18.
28. Nave R, Watz H, Hoffmann H, Boss H, Magnussen H. Deposition and metabolism of inhaled ciclesonide in the human lung. Eur Respir J. 2010;36(5):1113-1119.
29. Richter K, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol. 2005;45(2): 146-152.
30. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol. 2005;61(3):203-208.
31. Thongngarm T, Silkoff PE, Kossack WS, Nelson HS. Hydrofluoroalkane-- 134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma. J Asthma. 2005;42(4): 257-263.
32. Hoshino M. Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol Int. 2010;59(1):59-66.
33. Harrison TW, Wisniewski A, Honour J, Tattersfield AE. Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax. 2001;56(3):186-191.
34. Nave R, Zech K, Bliesath H, Bethke T. Differences between pharmacokinetics of ciclesonide-active principle and budesonide following repeated dose inhalations. Eur Respir J. 2003;22:S45.
35. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther. 2005;12(3):201-209.
36. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet. 2000;356(9229):556-561.
37. Nave R, Gunawardena KA, Zech K, Bethke TD. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyrylciclesonide in healthy subjects and patients with asthma are similar. Int J Clin Pharmacol Ther. 2006;44(1):1-7.
38. Nave R, Bethke T., van Marle SP, Zech K. Pharmacokinetics of [14C] ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet. 2004;43(7):479-486.
39. Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol. 2004;44(1):37-47.
40. Daley-Yates PT, Price AC, Sisson JR, Pereira A, Dallow N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol. 2001;51(5):400-409.
41. Nave R. Determination of lung deposition following inhalation of ciclesonide using different bioanalytical procedures. Bioanalysis. 2010;2(4):807-814.
42. Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273-282.
43. Gabrio BJ, Stein SW, Velasquez DJ. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int J Pharm. 1999;186(1):3-12.
44. Chapman KR, Voshaar TH, Virchow JC. Inhaler choice in primary practice. Eur Respir Rev. 2011;14(96):117-122.
45. Khassawneh BY, Al-Ali MK, Alzoubi KH, et al. Handling of inhaler devices in actual pulmonary practice: metered-dose inhaler versus dry powder inhalers. Respir Care. 2008;53(3):324-328.
46. Drollmann A, Nave R, Steinijans VW, Baumgärtner E, Bethke TD. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation. Clin Pharmacokinet. 2006;45(7):729-736.
47. Boss H, Minic P, Nave R. Similar results in children with asthma for steady state pharmockinetic parameters of ciclesonide inhaled with or without spacer. Clinical Medicine Insights: Pediatrics. 2010;4: 1-10.
48. Williams RO 3rd, Patel AM, Barron MK, Rogers TL. Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI. Drug Dev Ind Pharm. 2001;27(5): 401-412.
49. Pedersen S, Potter P, Dachev S, et al. Efficacy and safety of three ciclesonide doses vs placebo in children with asthma: the RAINBOW study. Respir Med. 2010;104(11):1618-1628.
50. van den Berge M, Ten Hacken NHT, van der Wiel E, Postma DS. Treatment of the bronchial tree from beginning to end: Targeting small airways inflammation in asthma. Allergy. 2013;68(1):16-26.